logo
Plus   Neg
Share
Email

Astellas Pharma To Buy Audentes Therapeutics In $3 Bln Deal

Astellas Pharma Inc agreed to acquire Audentes Therapeutics Inc. (BOLD) for US$60.00 per share in cash, representing a total equity value of about US$3 billion.

The offer price represents a premium of 110% to Audentes' closing share price of US$28.61 on December 2, 2019.

Asilomar will commence a tender offer for all outstanding shares of common stock of Audentes. The Tender Offer period is expected to commence in the next few weeks and to expire 20 business days after its commencement, unless otherwise extended.

Astellas said it is still reviewing the impact of a consummation of the transaction on its financial results for the fiscal year ending March 31, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PCNA has recalled about 5,000 units of Spare 10,000 mAh Power Banks for possible fire and burn hazards, the U.S. Consumer Product Safety Commission said in a statement. These include 445 units sold in Canada. The company said the power bank's lithium-ion battery can overheat and ignite, causing fire and burn hazards. Hundreds of Amazon workers have openly criticized the company's record on climate change by intentionally defying a company-wide ban against speaking out. More than 350 employees of the e-commerce giant criticized the company's climate change policy in a Medium blog post Sunday, putting their jobs at risk for violating the company's corporate communications policy. Loneliness at the workplace is on the rise in America and is resulting in less productivity as well as lower retention levels, a new study showed. According to Cigna's 2020 Loneliness Index, three out of five adults, or 61 percent, consider themselves lonely. This represents a seven percentage point increase from 2018. The study surveyed more than 10,400 adults.
Follow RTT
>